{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-258907","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.225750+00:00","generated_at":"2026-06-23T05:08:14.025128+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lyell Immunopharma receives FDA IND clearance for LYL845 TIL therapy for solid tumors","bullets":["FDA cleared IND for LYL845, an autologous TIL therapy enhanced with Epi-R reprogramming technology.","Phase 1 trial initially enrolling relapsed/refractory metastatic or locally advanced melanoma; expansion into NSCLC and colorectal cancer.","Initial clinical data expected in 2024; patient screening to begin in coming months.","LYL845 is Lyell's first TIL product candidate and second wholly owned IND clearance within the past year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-258907","json":"https://secwatch.observer/filing/0001193125-22-258907.json","markdown":"https://secwatch.observer/filing/0001193125-22-258907.md","text":"https://secwatch.observer/filing/0001193125-22-258907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522258907/0001193125-22-258907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522258907/d407382d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:08:14.025128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}